Site Map
About
- Celgene History
- Compliance
Bolder Science
Celgene Corporate Responsibility
- CDP (Carbon Disclosure Project) Reports
- Patients First
- Patient Safety, Support & Advocacy
- Patient Safety
- 2019 Innovation Impact Award
- Celgene Cooperation With European Patient Organizations
- EFPIA Spend Transparency Disclosure
- Advocacy Partnerships
- Patient Safety, Support & Advocacy
- Pre-Approval Access
- Global Health
- Patient Support
- Business with Integrity
- Funding
- Corporate Responsibility Reports
Community Guidelines
Contact Us
Diseases
- Acute Myeloid Leukemia
- Beta Thalassemia
- Indolent NHL
- Multiple Myeloma
- Beh?et’s Disease
- Multiple Sclerosis
- Myelofibrosis
- Myelodysplastic Syndromes
- Pancreatic Cancer
- Psoriasis and Psoriatic Arthritis
Global Office Locations
Home Page
Investors
Medical Professionals
Newsroom
Patients
Patients’ Partners at SABCS 2019
Patients’ Partners Event at ASH 2019
Privacy Policy
Research & Development
- Pipeline
- Medical Innovation
- Research & Development Centers
- Clinical Trials
- Celgene Global Drug Safety and Risk Management
- Celgene Medical Affairs
- Registry Studies
Thanks for Verifying
Therapies
October 30, 2019
Light The Night: How To Organize 1 Million People to Fight Blood Cancer
October 18, 2019
Understanding the Complexities of a Myelofibrosis Diagnosis
September 4, 2019
Blood Cancer Awareness Month: Fulfilling a Long-term Goal
May 8, 2019
Growing Up with Beta-Thalassemia: Taking Charge of Your Care
May 2, 2019
Is CAR T Cell Therapy the Next Step for Multiple Myeloma Treatment?
April 12, 2019
Celgene and Bristol Myers Squibb Stockholders Approve Combination to Create Innovative Biopharma Leader with Global Reach and Scale
April 3, 2019
Targeting the Tumor Microenvironment May Be a Key Development in Follicular Lymphoma Treatment
March 25, 2019
Why Myelofibrosis Remains Difficult to Treat
March 1, 2019
The Orphan Drug Act Continues To Give Hope to Patients with Rare Diseases
February 12, 2019